SIGLECs are a family of type I transmembrane proteins that are predominantly expressed by hemopoietic cells and they play critical roles in immune cell signalling and discrimination of self and nonself. The SIGLECs act as checkpoints in immune responses in human diseases including cancer, asthma, allergy, neurodegeneration, and autoimmune diseases and are being investigated as therapeutic targets [3-4].

1. Bernstein ID. (2000) Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia, 14 (3): 474-5. [PMID:10720144]

2. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. (1992) Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res, 52 (24): 6761-7. [PMID:1458463]

3. Duan S, Paulson JC. (2020) Siglecs as Immune Cell Checkpoints in Disease. Annu Rev Immunol, 38: 365-395. [PMID:31986070]

4. Gibbons A. (2020) How an ancient microbial arms race remodeled human cells. Science, 369 (6503): 491-492. [PMID:32732402]

5. Zheng X, Wu W, Liu Y, Zheng P. (2013) Methods of use of soluble cd24 for therapy of rheumatoid arthritis. Patent number: US20130231464A1. Assignee: Oncolmmune, Inc.. Priority date: 28/04/2010. Publication date: 05/09/2013.